AI-ready supply chain data in pharma is complete, consistent, current, traceable to its source, and representative of the lanes it describes. In practice that means one definition per lane, verified shipment position and time, packaging data tied to the conditions it was proven for, and a record of who changed what. A short self-test at the end shows where a team stands.
The first four echo the ALCOA+ principles that WHO sets for GxP records: attributable, legible, contemporaneous, original, and accurate, plus complete, consistent, enduring, and available (WHO TRS 1033, Annex 4). Quality teams already work to this standard. AI readiness extends it to the data a model reads.
A lane record needs origin, destination, mode, carriers, handover points, and the season it applies to. The EU Guidelines on Good Distribution Practice already expect that logic: “Risk assessment of delivery routes should be used to determine where temperature controls are required” (section 9.2), and temperature mapping “should take into account seasonal variations” (section 9.4) (EU GDP Guidelines, 2013/C 343/01).
Packaging data follows the same rule. A qualification result carries a lane, a season, and a payload profile. Stored without them, it looks usable and misleads a model that applies it to a different lane.
One lane under three names splits its history into three thin records. A model sees three weak signals where the team has one strong one.
Position comes first. Nico Ros, SkyCell's CTO and co-founder, made the case in his LogiPharma masterclass: enrichment data such as weather or airport conditions only helps when the shipment's location is correct (SkyCell blog, May 2024).
Time comes next. EY lists timestamp mismatches among the flaws that stall AI pilots in pharma manufacturing, next to data silos and poor data lineage (EY, January 2026). A dwell time calculated across two time zones can be off by hours, and every downstream score inherits the error.
The GDP Guidelines set the baseline: “Records should be made at the time each operation is undertaken” (section 4.2), and “Records should be kept so that the actual location of the product can be known” (section 5.8).
Brian Thornley, VP Supply Chain Excellence at Moderna, put it plainly on a panel reported by SkyCell: “your master data has to be as good as possible, otherwise you just go towards chaos” (SkyCell blog, May 2025).
Shared definitions make master data work across partners. The same lane code, product class, and handover point need one meaning for the shipper, the forwarder, and the handler. EY's proposal for pharma data is a common data model with federated governance: central standards, local flexibility.
Traceability closes the loop. If a score moves overnight, the team should be able to name the input that moved it. That is the difference between a recommendation a quality manager can defend and one that gets ignored.
Can your team answer these about last month's shipments without opening a spreadsheet?
Five yes answers mean the foundation is ready for AI. Each no points to the first thing to fix.
A lane risk assessment on Validaide produces structured lane data as part of the work. Each assessment uses the same method and the same attributes, so the lane definition stays consistent from one assessment to the next. More than 70,000 lanes are digitized and assessed on the platform.
The Dynamic Pharma Index draws on real shipment performance and incident history, alongside temperature exposure, packaging protection, supplier quality, security, and route complexity. Logger and external data feed the same lane record. The index draws on verified data from 2,094 qualified suppliers.
Shippers and forwarders work from that shared record. Six of the top 10 pharma companies use Validaide, and all of the top 20 freight forwarders are connected.
For the program view, see how to build a data-driven cold chain risk program and the cold chain KPIs that predict failure.
AI-ready pharma supply chain data is complete, consistent, current, traceable, and representative of the lanes it describes. The questions below cover what matters most and how Validaide helps create it.
Data that is complete, consistent, current, traceable to its source, and representative of the lanes and events a model will meet. Gartner adds that data with issues is not ready for AI.
Shipment position and time come first, because every enrichment (weather, airport conditions, dwell) depends on them. Lane definitions and packaging qualification data come next.
They overlap. The ALCOA+ principles (attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available) already describe good records. AI readiness adds representativeness: the data must cover the patterns and rare events the model will face.
No. Pick one problem, such as one lane portfolio, and fix its data first. EY's authors recommend the same approach: target one pressing issue, fix its data, then apply AI.
Every data set needs a named owner. Governance should sit inside the quality system, as WHO's data integrity guideline expects for GxP data.
By applying one assessment method to every lane, connecting shippers and forwarders on a shared record, and feeding shipment performance into the Dynamic Pharma Index.
This article was written by Médb Kiely-Cuddy, Validaide’s content specialist, with assistance from generative AI. All content and facts were reviewed by a human before publication.